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Summary
Background.— Systematic use of a 28mm balloon has been proposed for pulmonary vein cry-
oisolation in patients with atrial ﬁbrillation.
Objective.— To assess the results of a dual balloon size strategy using a 23 or 28mm cryoballoon
catheter for pulmonary vein isolation.
Methods.— A total of 118 patients (mean age 56± 10 years) with paroxysmal (n = 85) or per-
sistent atrial ﬁbrillation (n = 33) were enrolled. Patients with four pulmonary veins < 20mm in
diameter were isolated with a 23mm cryoballoon (n = 29); patients with one pulmonary vein
diameter ≥ 20mm were isolated with a 28mm cryoballoon (n = 89).
Results.— No signiﬁcant difference in procedural variables was observed between the two
groups. AF-free survival, after a mean follow-up of 19.9± 5months, was similar in the two
groups (69% vs 62%; p = 0.57 and between patients with paroxysmal atrial ﬁbrillation (68% vs
68%; p = 0.91) or persistent AF (75% vs 48%; p = 0.60). AF duration before the ablation procedure
(p = 0.005) was an independent predictor of AF recurrence. Phrenic nerve palsy rate was not
Abbreviations: AF, atrial ﬁbrillation; PV, pulmonary veins; RSPV, right superior pulmonary vein; CI, conﬁdence interval; mGy, milligrays.
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statistically different in the two groups (4 [14%] vs 9 [10%]; p = 0.73). The temperature in the
right superior pulmonary vein (p = 0.008) was an independent predictor of phrenic nerve palsy.
Five patients developed left atrial ﬂutter with the 28mm diameter balloon versus none with
the 23mm balloon.
Conclusions.— A dual balloon size strategy was not associated with a lower AF-free survival
or a higher procedure-related complication rate in patients in whom the 23mm balloon was
used. Pulmonary vein isolation with a 23mm cryoballoon catheter appears to be an appropriate
option in selected patients with small pulmonary vein diameters.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Background.— L’utilisation systématique d’un ballon de 28mm a été proposée pour la cryo-
isolation des veines pulmonaires (VP) chez les patients ayant une ﬁbrillation atriale (FA).
Objectif.— Évaluer une stratégie utilisant deux tailles de ballon (23 ou 28mm) pour l’isolation
des VP.
Méthode.— Cent dix-huit patients (âge moyen 56± 10 ans) ayant une FA paroxystique (n = 85)
ou une FA persistante (n = 33) ont été inclus. Les patients dont le diamètre des quatre
VP est inférieur à 20mm ont été isolé avec un ballon de 23mm (n = 29), et ceux dont
le diamètre d’une des VP est supérieure ou égale à 20mm avec un ballon de 28mm
(n = 89).
Résultats.— Les paramètres procéduraux sont similaires dans les deux groupes. À 19,9± 5mois,
le maintien du rythme sinusal est comparable dans les deux groupes (69 % versus 62 % ;
p = 0,57), chez les patients ayant une FA paroxystique (68 % versus 68 % ;p = 0,91) et une
FA persistante (75 % versus 48 % ; p = 0,60). La durée de la FA avant l’ablation (p = 0,005)
est identiﬁé comme facteur prédictif indépendant de la récidive. La paralysie du nerf
phrénique est comparable dans les deux groupes (quatre [14 %] versus neuf [10 %] ; p = 0,73).
La température dans la VP supérieure droite (p = 0,008) est un facteur prédictif indépen-
dant de la paralysie du nerf phrénique. Cinq patients développent un ﬂutter atrial dans le
groupe traité avec un ballon de 28mm et aucun dans le groupe traité avec un ballon de
23mm.
Conclusion.— Dans la stratégie utilisant deux tailles de ballons pour la cryo-isolation des VP,
le ballon de 23mm n’est pas associé à mauvais résultat ni à un taux de complication élevé.
L’utilisation du ballon de 23mm paraît être une alternative appropriée pour des patients sélec-
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Introduction
PV isolation with radiofrequency is an established treatment
option for patients with AF. Use of radiofrequency cures AF
episodes in 50—70% of patients [1—3]. Cryoablation is an
alternative strategy developed to overcome some of the dis-
advantages of radiofrequency [4]. Recently, a double-lumen
cryoballoon catheter (Arctic Front, Cryocath Technologies,
Montreal, Canada) was used for circumferential PV isola-
tion. This catheter is available in two sizes: 23 and 28mm
diameter. Previous clinical studies have demonstrated that
cryoablation is a safe and effective method for PV isolation
[5—8]. The major reported complication of a cryoballoon
catheter is right phrenic nerve palsy [5,9]. In one study,
this complication was observed mainly with the 23mm cry-
oballoon catheter [9]. Other authors have suggested that
systematic use of a 28mm cryoballoon catheter may reduce
the incidence of phrenic nerve palsy [10].The objective of this study was to assess the results of
a dual balloon size strategy with a 23 or a 28mm cryobal-
loon catheter for PV isolation and to compare the results
according to balloon size.
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ethods
atients
total of 118 consecutive patients were enrolled prospec-
ively between July 2006 and September 2009, for PV
ryoballoon isolation for symptomatic AF. All patients pro-
ided written informed consent. Inclusion criteria were:
istory of highly symptomatic paroxysmal or persistent AF
espite treatment with at least one antiarrhythmic drug.
xclusion criteria were the presence of left atrial thrombus
nd a left atrial surface area > 35 cm2. Of the 118 patients,
9 underwent PV isolation with a 23mm cryoballoon and 89
ere treated with a 28mm cryoballoon.
reablation
efore ablation, all patients attended a clinical visit with
eview of medical records including electrocardiograms and
olter electrocardiogram documenting AF. The medical his-
ory was obtained and the risks of ablation were discussed
n detail with the patient. All patients had received effec-
ive anticoagulation for ≥ 1 month, with a weekly assessed
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nternational normalized ratio > 2. Oral anticoagulation was
topped 4 days before the procedure and replaced by a daily
urative dose of fractionated heparin.
blation procedure
efore the procedure, detailed information on left atrial
natomy was obtained by computed tomography and PV
iameters were measured in order to select the more appro-
riate cryoballoon (Arctic Front, Cryocath) size. Two balloon
atheter sizes are available (23mm and 28mm diameters).
23mm cryoballoon catheter was preferred when the max-
mum diameter of all four PVs was < 20mm and a 28mm was
sed when the diameter of one of the PVs was ≥ 20mm.
ll procedures were performed with the patient under deep
edation.
A 6F decapolar catheter was placed in the coronary sinus
ia the right jugular vein, and a 6F quadripolar catheter
as placed in the His bundle region via the right femoral
ein. A single transseptal puncture was performed under
uoroscopic guidance via a right femoral vein approach. A
0—100 IU/kg intravenous heparin bolus was given and a con-
inuous infusion was administered to maintain the activated
lotting time > 300 s. The transseptal sheath was exchanged
or the 12 F transseptal sheath (FlexCath, Montreal, Canada)
n order to introduce the cryoballoon catheter into the left
trium. Before PV isolation, a circular mapping catheter
Lasso, Biosense Webster Inc., Diamond Bar, CA, USA) was
dvanced into each PV ostium to obtain the baseline elec-
rical pattern. The transseptal sheath was ﬂushed constantly
ith heparinized saline. After withdrawing the mapping
atheter, a 23 or 28mm cryoballoon was advanced over the
ire in the left atrium, inﬂated and positioned at the ostium
f each PV. Vessel occlusion was assessed by a selective con-
rast injection and graded on a semiquantitative scale from
to 4. An occlusion was considered to be grade 4 when selec-
ive contrast injection showed total contrast retention with
o backﬂow into the atrium, grade 3 when contrast injec-
ion showed minimal backﬂow into the atrium, grade 2 when
ontrast injection showed mild backﬂow into the atrium and
rade 1 when contrast injection showed immediate rapid
utﬂow from the PV. Cryoenergy was given for 240 s per
pplication and consisted of a minimum of two applications
or each vein. During the freezing cycle, local tempera-
ure from a sensor at the proximal part of the cryoballoon,
nd oesophageal temperature from an oesophageal probe
ere monitored continuously. Before right superior PV abla-
ion, a quadripolar catheter was positioned in the superior
ena cava for continuous phrenic nerve stimulation dur-
ng cryoablation. The application was terminated on loss
f stimulation. After targeting all PVs, the cryocatheter
as exchanged for the mapping catheter to check for any
emaining electrical activity. PV isolation was considered to
e complete when the loss of all PV potentials was recorded,
nd partial when residual PV potentials were recorded. If
he recording showed partial isolation, the cryoballoon was
epositioned.ollow-up
fter ablation, patients were treated with intravenous hep-
rin. Oral anticoagulation was started on the day after the
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rocedure. All patients were reviewed in the outpatient
linic after 3 months. Follow-up included physical exami-
ation, telephone contact, electrocardiographic and Holter
onitoring at 3 months and 6 months. In December 2009
ecent data (Holter and medical records < 2 months) or tele-
hone contact were obtained for all patients. AF recurrence
as deﬁned as documented AF episodes lasting > 30 s.
tatistical analysis
tatistical analysis was performed with SPSS 11.0 (SPSS
nc., Chicago, Illinois, USA). Quantitative variables were
xpressed as mean± standard deviation and were compared
ith Student’s t-test. Categorical variables were expressed
s percentages and were compared with the Chi2 test. The
umulative probability of AF-free survival was estimated by
he Kaplan—Meier actuarial methods, at 1-month intervals.
he log rank test was used to determine any signiﬁcant
ifference. A multivariate logistic regression model was
sed to identify factors predictive of phrenic nerve palsy.
ultivariate Cox regression models were used to identify
actors predictive of AF-free survival and were systemati-
ally adjusted for age and sex. A probability of p < 0.05 was
onsidered statistically signiﬁcant.
esults
total of 118 patients (91 men) with a mean age of 56± 10
ears were included in the study. Indications for PV isolation
ere symptomatic paroxysmal AF in 85 (72%) patients and
ersistent AF in 33 (28%) patients. The mean procedure time
as 185min, the mean cryoenergy time was 39min and the
ean ﬂuoroscopy exposure was 509mGy.
linical and procedural characteristics
ables 1 and 2, respectively, show the clinical and proce-
ural characteristics for the two groups. Body mass index
p = 0.04) and left atrial surface area (p < 0.001) were signif-
cantly lower in the 23mm balloon group. The ratio between
V and balloon sizes was lower in the 28mm balloon group
p < 0.001). Procedural characteristics were similar in both
roups. When detailed variables of each PV isolation were
ompared (Table 2), a higher occlusion grade was observed
or the left inferior PV (p = 0.004), right superior PV (RSPV)
p = 0.03) and right inferior PV (p = 0.001) in the 23mm bal-
oon group. A lower cryoenergy temperature of all PVs was
igniﬁcantly associated with PV isolation using a 23mm bal-
oon.
aintenance of sinus rhythm
ean follow-up was at 19.9± 5 months. No patients were
ost to follow-up. The mean AF-free survival time to ﬁrst
ocumented AF was 13± 7 months (range 3—37). The overall
F-free survival rate was 64%. The actuarial AF-free survival
ate was not signiﬁcantly different according to balloon size
69% vs 62%, p = 0.57) (Fig. 1). No signiﬁcant difference for
F-free survival was observed in the subgroup of patients
ith paroxysmal (17 [68%] vs 41 [68%], p = 0.91 or persis-
ent AF (3 [75%] vs 14 [48%], p = 0.60. After adjustment for
ge, sex, AF type and left atrial size, the AF duration (odds
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Table 1 Clinical characteristics of the two groups.
Parameters 23mm balloon (n = 29) 28mm balloon (n = 89) p
Age (years) 54± 13 57± 9 0.15
Men/women (n) 15/14 76/13 < 0.001
Body mass index (kg/m2) 26± 5 29± 8 0.04
High blood pressure, n (%) 11 (39) 42 (48) 0.43
Other heart disease, n (%) 6 (21) 21 (18) 0.27
AF duration (years) 3.9± 4.2 3.9± 4.0 0.99
Paroxysmal AF, n (%) 25 (86) 60 (67) 0.05
Persistent AF, n (%) 4 (14) 29 (32) 0.06
Left atrial surface area (cm2) 20± 4 25± 6 < 0.001
Maximal PV diameter (mm) 19± 2 20± 2 < 0.001
PV diameter/balloon diameter (mm) 0.81 0.72 < 0.001
n
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lAF: atrial ﬁbrillation; PV: pulmonary vein.
ratio 1.009, 95% CI 1.003—1.015, p = 0.005) was identiﬁed
as an independent predictor of ﬁrst documented AF recur-
rence in multivariate Cox models. The AF recurrence rate
was identical in the two groups.
Complications
The right phrenic nerve palsy rate was similar in the two
groups (4 [14%] vs 9 [10%], p = 0.73). Detailed data from
patients with phrenic nerve palsy are shown in Table 3.
Complete recovery of phrenic nerve palsy was observed
during follow-up in all patients. Seven of these patients
presented persistent phrenic nerve palsy for > 3 months in
the 28mm balloon group. Two of the four cases of phrenic
i
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Table 2 Procedural variables.
Variable 23mm balloon (n = 29)
Procedure time (min) 189± 32
Balloon in/out time (min) 74± 17
Cryotherapy time (min) 40± 10
Fluoroscopy time (min) 13± 9
Minimal temperature (◦C)
Left superior PV —64± 9
Left interior PV —59± 10
Right superior PV —64± 7
Right inferior PV —60± 7
Occlusion grade 4
Left superior PV 3.6± 0.5
Left interior PV 3.5± 0.5
Right superior PV 3.9± 0.4
Right inferior PV 3.7± 0.5
Complete isolation, n (%)
Left superior PV 23 (79)
Left interior PV 26 (90)
Right superior PV 28 (99)
Right inferior PV 25 (86)
PV: pulmonary vein.erve palsy observed in the 23mm balloon group recov-
red after stopping cryotherapy during the procedure and
ne patient recovered after 1 week. In a multivariate logis-
ic regression model (including balloon size, RSPV occlusion
rade, minimum RSPV temperature), minimum RSPV tem-
erature (hazard ratio: 1.1; 95% CI: 1.0—1.2, p = 0.008) was
dentiﬁed as an independent predictor of phrenic nerve
alsy.
Five patients in the 28mm balloon group developed
eft atrial ﬂutter during follow-up. The other complications
n the 28mm balloon group were tamponade, transient
schaemic attack and spontaneous resolving oesophageal
lceration. No complications were observed in the 23mm
alloon group.
28mm balloon (n = 89) p
184± 35 0.51
72± 15 0.56
39± 9 0.56
12± 7 0.55
—50± 8 < 0.001
—45± 8 < 0.001
—51± 9 < 0.001
—43± 7 < 0.001
3.7± 0.6 0.56
3.1± 0.7 0.004
3.6± 0.7 0.03
3.1± 0.8 0.001
79 (90) 0.21
64 (73) 0.07
84 (96) 0.57
59 (66) 0.054
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Table 3 Phrenic nerve palsy.
Patients Balloon size (mm) RSPV temperature (◦C) RSPV occlusion PNP recovery
1 23 —60 4 < 7 days
2 23 —75 4 Per procedure
3 28 —60 4 > 6 months
4 23 —69 4 < 1 day
5 23 —62 4 Per procedure
6 28 —63 4 > 6 months
7 28 —64 4 > 6 months
8 28 —59 4 > 3 months
9 28 —60 4 > 3 months
10 28 —72 4 > 6 months
11 28 —62 4 > 4 months
12 28 —59 4 Per procedure
13 28 —60 4 > 6 months
RSPV: right superior pulmonary vein; PNP: phrenic nerve palsy.
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he main ﬁnding of this prospective observational study
ncluding 118 consecutively enrolled patients is that a dual-
alloon-size strategy was not associated with lower AF-free
urvival or a higher procedure-related complication rate in
atients treated with a 23mm diameter balloon. Procedu-
al variables, phrenic nerve palsy and clinical outcomes of
atients were similar when cryoballoon catheter size was
elected according to the size of the PVs. These results sug-
est that PV isolation with a 23mm cryoballoon catheter
s an appropriate option in selected patients with small PV
iameters.
igure 1. Kaplan—Meier survival curve performed to estimate AF
reedom survival.
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luoroscopy duration, cryoenergy time and total procedure
ime were similar between the two groups in this study. Simi-
ar results were reported by Neumann et al. [9]. Ahmed et al.
eported no signiﬁcant difference in the oesophageal tem-
erature drop between the use of the 23 and 28mm balloon
atheters [11]. Ayer et al. reported a signiﬁcant associa-
ion between obesity and increased left atrial size in a large
ohort and hypothesized that this might partly explain the
ssociation between obesity and AF [12]. Accordingly, a high
ody mass index and a large atrial size were observed signif-
cantly more frequently in patients in the 28mm diameter
alloon group.
inus rhythm maintenance
he mean AF-free survival time to the ﬁrst documented
pisode of AF was 13± 7 months in this study. Previous stud-
es using cryoenergy for the ablation of re-entrant atrionodal
r atrioventricular tachycardia have shown a higher recur-
ence rate than with radiofrequency [13]. Linhart et al.
ound that PV ablation with the cryoballoon technique had
similar success rate to that of radiofrequency ablation
14]. In the series reported by Van Belle et al., freedom
rom AF after 3 months was achieved in 60% of patients
5]. After a mean follow-up of 12 months, Neumann et al.
chieved maintenance of sinus rhythm in 74% of patients
ith paroxysmal AF and 42% of patients with persistent AF.
lein et al. reported 86% of freedom from AF at 6 months
n patients with paroxysmal AF [7]. In our study including
atients with paroxysmal and persistent AF, 63% of patients
ere free from AF with a follow-up of 19± 5 months after
single procedure. Our results are similar to the clinical
fﬁcacy reported in previous studies. After adjustment for
linical variables, AF duration before the ablation procedure
as identiﬁed as an independent predictor of AF recur-
ence.
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Complications
The most frequent complication after balloon catheter abla-
tion was phrenic nerve palsy [5,9,15]. Neumann et al.
reported phrenic nerve palsy in 24 of 26 patients who under-
went ablation with a 23mm balloon, and in only two patients
who underwent ablation with a 28mm cryoballoon [9]. Van
Belle et al. reported cases of phrenic nerve palsy occurring
during cryoablation with a 23mm balloon deep inside the
RSPV and advised caution when using 23mm balloon in deep
regions [5]. Klein et al. reported one case of phrenic nerve
palsy with a 23mm cryoballoon catheter and two cases with
a 28mm cryoballoon catheter and considered that the devel-
opment of phrenic nerve palsy was independent of balloon
size [7]. With ‘the single big cryoballoon’ strategies, phrenic
nerve palsy occurred when the cryothermal energy was
deployed inside the septal PVs and the authors suggested
that the ratio between PV and balloon size (≥ 0.93) may be
valuable to estimate the risk of phrenic nerve palsy [10]. In
the present study, the mean ratio between PV and catheter
size was < 0.93 in the two groups. The phrenic nerve palsy
rate was similar between the two groups. The reason why
some patients develop phrenic nerve palsy and others do not
remains unclear [16]. A possible explanation for the devel-
opment of phrenic nerve palsy in the present series may
be unintentional deployment of cryothermal energy inside
the septal PVs [7]. Another explanation may be the vari-
able anatomical relations between the right phrenic nerve
and the heart [17,18]. The minimum temperature during
RSPV freezing was found to be an independent predictor of
phrenic nerve palsy in this study.
Big cryoballoon (28mm) strategies use an intentionally
oversized balloon covering the proximal left antrum region
situated away from the phrenic nerve. This may lead to a
re-entrant circuit due to a large cryolesion. In the present
study, sustained atypical left atrial ﬂutter was observed
during follow-up in ﬁve patients treated with a 28mm cry-
oballoon. Cryoballoon ablation has been reported to cause
signiﬁcant reversible oesophageal ulceration [1]. In this
study, reversible oesophageal ulceration was observed in a
patient treated by a 28mm cryoballoon, who underwent
systematic endoscopy due to a lower oesophageal lumen
temperature.
Limitations
This is a small non-randomized study with a small number
of patients, comparing patients with symptomatic drug-
refractory AF who underwent cryoablation with a 23mm
cryoballoon catheter and a 28mm cryoballoon catheter. This
type of comparison only applies to patients with small veins
and is difﬁcult to perform. Subgroup comparisons were not
performed because of the small number of patients.
ConclusionIn this study, the results of a dual balloon size strategy
using a 23 or 28mm cryoballoon catheter for PV isola-
tion appear equivalent, when cryoballoon catheter size was
chosen according to PV size. The rates of right phrenic
[75
erve palsy and AF recurrence were statistically simi-
ar with the 23 and 28mm cryoballoon catheters in PV
solation. Left atrial ﬂutter was observed only with the
8mm cryoballoon catheter. These results suggest that
V isolation with a 23mm cryoballoon catheter is an
ppropriate option in selected patients with a small PV diam-
ter.
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